Pathology: mML - L1 - all population; mML - L1 - BRAF mutant; mML - L1 - BRAF wild;
| mML - L1 - all population | mML - L1 - BRAF mutant | mML - L1 - BRAF wild | |||||||||||
| CheckMate 067 (N vs I ; all population), 2015 | CheckMate 064, 2016 | CheckMate 067 (NI vs I ; all population), 2015 | CheckMate 069 (all population), 2015 | CheckMate 067 (NI vs N) EXPLORATORY, 2015 | RELATIVITY-047, 0 | A3671009, 2013 | IMspire-150 (BRAF mutant), 2020 | CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 | IMspire-170, 2020 | CheckMate 066, 2015 | CheckMate 069 (BRAF wild type), 2015 | ||
| nivolumab plus ipilimumab | 5 | T1 | T1 | T1 | T1 | T1 | |||||||
| nivolumab alone | 2 | T1 | T0 | T0 | T1 | ||||||||
| relatlimab plus nivolumab | 1 | T1 | |||||||||||
| atezolizumab plus SoC | 1 | T1 | |||||||||||
| atezolizumab plus cometinib | 1 | T1 | |||||||||||
| nivolumab followed by ipilimumab | 1 | T1 | |||||||||||
| tremelimumab | 1 | T1 | |||||||||||
| placebo plus SoC | 0 | T0 | |||||||||||
| pembrolizumab alone | 0 | T0 | |||||||||||
| ipilimumab followed by nivolumab | 0 | T0 | |||||||||||
| ipilimumab alone | 0 | T0 | T0 | T0 | T0 | T0 | |||||||
| dacarbazine | 0 | T0 | |||||||||||
| Standard of Care (SoC) | 0 | T0 | |||||||||||